ARG1 and melanoma: Indeed, the frequency of ARG1-expressing MDSCs significantly discriminate PDAC metastatic patients suggesting that these cells have a pro-metastatic potential (31), as well as the reduction of ARG1+ cells in melanoma patients after Ipilimumab-based treatment highlights that the therapeutic efficacy of this immune-based treatment might involve a systemic effect on MDSC accumulation (84).